COVID-19: Discovery, diagnostics and drug development

Coronavirus disease 2019 (COVID-19) started as an epidemic in Wuhan in 2019, and has since become a pandemic. Groups from China identified and sequenced the virus responsible for COVID-19, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and determined that it was a novel coronavi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of hepatology 2021-01, Vol.74 (1), p.168-184
Hauptverfasser: Asselah, Tarik, Durantel, David, Pasmant, Eric, Lau, George, Schinazi, Raymond F.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 184
container_issue 1
container_start_page 168
container_title Journal of hepatology
container_volume 74
creator Asselah, Tarik
Durantel, David
Pasmant, Eric
Lau, George
Schinazi, Raymond F.
description Coronavirus disease 2019 (COVID-19) started as an epidemic in Wuhan in 2019, and has since become a pandemic. Groups from China identified and sequenced the virus responsible for COVID-19, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and determined that it was a novel coronavirus sharing high sequence identity with bat- and pangolin-derived SARS-like coronaviruses, suggesting a zoonotic origin. SARS-CoV-2 is a member of the Coronaviridae family of enveloped, positive-sense, single-stranded RNA viruses that infect a broad range of vertebrates. The rapid release of the sequence of the virus has enabled the development of diagnostic tools. Additionally, serological tests can now identify individuals who have been infected. SARS-CoV-2 infection is associated with a fatality rate of around 1–3%, which is commonly linked to the development of acute respiratory distress syndrome (ARDS), likely resulting from uncontrolled immune activation, the so called “cytokine storm”. Risk factors for mortality include advanced age, obesity, diabetes, and hypertension. Drug repurposing has been used to rapidly identify potential treatments for COVID-19, which could move quickly to phase III. Better knowledge of the virus and its enzymes will aid the development of more potent and specific direct-acting antivirals. In the long term, a vaccine to prevent infection is crucial; however, even if successful, it might not be available before 2021-22. To date, except for intravenous remdesivir and dexamethasone, which have modest effects in moderate to severe COVID-19, no strong clinical evidence supports the efficacy of any other drugs against SARS-CoV-2. The aim of this review is to provide insights on the discovery of SARS-CoV-2, its virology, diagnostic tools, and the ongoing drug discovery effort.
doi_str_mv 10.1016/j.jhep.2020.09.031
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7543767</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168827820336758</els_id><sourcerecordid>2508913143</sourcerecordid><originalsourceid>FETCH-LOGICAL-c586t-606bbfe345dab9748cd7c27241097a6f750a08d6963f2181eb2d5182884c649a3</originalsourceid><addsrcrecordid>eNp9kUtv1DAUhS0EokPhD7BAkdiwaML1MzaqkKop0EojdQNsLcd2ZhzlMdiTSP33eDSlgi5Y3YW_c-71OQi9xVBhwOJjV3U7v68IEKhAVUDxM7TCAqAEwfBztMqQLCWp5Rl6lVIHABQUe4nOKAUqGaUrxNd3P2-vS6w-Fdch2Wnx8f6icMFsxykdgk2FGV3h4rwtnF98P-0HPx5eoxet6ZN_8zDP0Y-vX76vb8rN3bfb9dWmtFyKQylANE3rKePONKpm0rrakpowDKo2oq05GJBOKEFbgiX2DXEcSyIls4IpQ8_R55Pvfm4G72xeHU2v9zEMJt7ryQT978sYdno7LbrmjNaizgYXJ4PdE9nN1UaHMfk4aGCYgKB8wRn_8LAvTr9mnw56yKH4vjejn-akCWNKcSU5zej7J2g3zXHMaWjCQSpMMTtS5ETZOKUUfft4BAZ9LFF3-liiPpaoQelcYha9-_vXj5I_rWXg8gT4nP0SfNTJBj9a70L09qDdFP7n_xvDM6qx</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2508913143</pqid></control><display><type>article</type><title>COVID-19: Discovery, diagnostics and drug development</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Asselah, Tarik ; Durantel, David ; Pasmant, Eric ; Lau, George ; Schinazi, Raymond F.</creator><creatorcontrib>Asselah, Tarik ; Durantel, David ; Pasmant, Eric ; Lau, George ; Schinazi, Raymond F.</creatorcontrib><description>Coronavirus disease 2019 (COVID-19) started as an epidemic in Wuhan in 2019, and has since become a pandemic. Groups from China identified and sequenced the virus responsible for COVID-19, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and determined that it was a novel coronavirus sharing high sequence identity with bat- and pangolin-derived SARS-like coronaviruses, suggesting a zoonotic origin. SARS-CoV-2 is a member of the Coronaviridae family of enveloped, positive-sense, single-stranded RNA viruses that infect a broad range of vertebrates. The rapid release of the sequence of the virus has enabled the development of diagnostic tools. Additionally, serological tests can now identify individuals who have been infected. SARS-CoV-2 infection is associated with a fatality rate of around 1–3%, which is commonly linked to the development of acute respiratory distress syndrome (ARDS), likely resulting from uncontrolled immune activation, the so called “cytokine storm”. Risk factors for mortality include advanced age, obesity, diabetes, and hypertension. Drug repurposing has been used to rapidly identify potential treatments for COVID-19, which could move quickly to phase III. Better knowledge of the virus and its enzymes will aid the development of more potent and specific direct-acting antivirals. In the long term, a vaccine to prevent infection is crucial; however, even if successful, it might not be available before 2021-22. To date, except for intravenous remdesivir and dexamethasone, which have modest effects in moderate to severe COVID-19, no strong clinical evidence supports the efficacy of any other drugs against SARS-CoV-2. The aim of this review is to provide insights on the discovery of SARS-CoV-2, its virology, diagnostic tools, and the ongoing drug discovery effort.</description><identifier>ISSN: 0168-8278</identifier><identifier>ISSN: 1600-0641</identifier><identifier>EISSN: 1600-0641</identifier><identifier>DOI: 10.1016/j.jhep.2020.09.031</identifier><identifier>PMID: 33038433</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Antiviral agents ; Antiviral Agents - pharmacology ; Coronaviridae ; Coronavirus ; Coronaviruses ; COVID-19 ; COVID-19 - diagnosis ; COVID-19 - physiopathology ; COVID-19 Drug Treatment ; Cytokine storm ; Cytokines ; Dexamethasone ; Diabetes mellitus ; Drug Development ; Drug Discovery ; Drug Repositioning ; Drug repurposing ; Genome, Viral ; Humans ; Immune response ; Immunity, Innate ; Immunosuppressive agents ; Intravenous administration ; Life Sciences ; Pandemics ; Pathogenesis ; Remdesivir ; Respiratory distress syndrome ; Respiratory Distress Syndrome - virology ; Review ; Risk Factors ; RNA viruses ; SARS-CoV-2 ; SARS-CoV-2 - drug effects ; SARS-CoV-2 - genetics ; Serological tests ; Severe acute respiratory syndrome coronavirus 2 ; Viruses</subject><ispartof>Journal of hepatology, 2021-01, Vol.74 (1), p.168-184</ispartof><rights>2020 European Association for the Study of the Liver</rights><rights>Copyright © 2020 European Association for the Study of the Liver. All rights reserved.</rights><rights>Copyright Elsevier Science Ltd. Jan 2021</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. 2020 European Association for the Study of the Liver</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c586t-606bbfe345dab9748cd7c27241097a6f750a08d6963f2181eb2d5182884c649a3</citedby><cites>FETCH-LOGICAL-c586t-606bbfe345dab9748cd7c27241097a6f750a08d6963f2181eb2d5182884c649a3</cites><orcidid>0000-0002-1881-8762</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jhep.2020.09.031$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33038433$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://inserm.hal.science/inserm-04120635$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Asselah, Tarik</creatorcontrib><creatorcontrib>Durantel, David</creatorcontrib><creatorcontrib>Pasmant, Eric</creatorcontrib><creatorcontrib>Lau, George</creatorcontrib><creatorcontrib>Schinazi, Raymond F.</creatorcontrib><title>COVID-19: Discovery, diagnostics and drug development</title><title>Journal of hepatology</title><addtitle>J Hepatol</addtitle><description>Coronavirus disease 2019 (COVID-19) started as an epidemic in Wuhan in 2019, and has since become a pandemic. Groups from China identified and sequenced the virus responsible for COVID-19, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and determined that it was a novel coronavirus sharing high sequence identity with bat- and pangolin-derived SARS-like coronaviruses, suggesting a zoonotic origin. SARS-CoV-2 is a member of the Coronaviridae family of enveloped, positive-sense, single-stranded RNA viruses that infect a broad range of vertebrates. The rapid release of the sequence of the virus has enabled the development of diagnostic tools. Additionally, serological tests can now identify individuals who have been infected. SARS-CoV-2 infection is associated with a fatality rate of around 1–3%, which is commonly linked to the development of acute respiratory distress syndrome (ARDS), likely resulting from uncontrolled immune activation, the so called “cytokine storm”. Risk factors for mortality include advanced age, obesity, diabetes, and hypertension. Drug repurposing has been used to rapidly identify potential treatments for COVID-19, which could move quickly to phase III. Better knowledge of the virus and its enzymes will aid the development of more potent and specific direct-acting antivirals. In the long term, a vaccine to prevent infection is crucial; however, even if successful, it might not be available before 2021-22. To date, except for intravenous remdesivir and dexamethasone, which have modest effects in moderate to severe COVID-19, no strong clinical evidence supports the efficacy of any other drugs against SARS-CoV-2. The aim of this review is to provide insights on the discovery of SARS-CoV-2, its virology, diagnostic tools, and the ongoing drug discovery effort.</description><subject>Antiviral agents</subject><subject>Antiviral Agents - pharmacology</subject><subject>Coronaviridae</subject><subject>Coronavirus</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - diagnosis</subject><subject>COVID-19 - physiopathology</subject><subject>COVID-19 Drug Treatment</subject><subject>Cytokine storm</subject><subject>Cytokines</subject><subject>Dexamethasone</subject><subject>Diabetes mellitus</subject><subject>Drug Development</subject><subject>Drug Discovery</subject><subject>Drug Repositioning</subject><subject>Drug repurposing</subject><subject>Genome, Viral</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immunity, Innate</subject><subject>Immunosuppressive agents</subject><subject>Intravenous administration</subject><subject>Life Sciences</subject><subject>Pandemics</subject><subject>Pathogenesis</subject><subject>Remdesivir</subject><subject>Respiratory distress syndrome</subject><subject>Respiratory Distress Syndrome - virology</subject><subject>Review</subject><subject>Risk Factors</subject><subject>RNA viruses</subject><subject>SARS-CoV-2</subject><subject>SARS-CoV-2 - drug effects</subject><subject>SARS-CoV-2 - genetics</subject><subject>Serological tests</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Viruses</subject><issn>0168-8278</issn><issn>1600-0641</issn><issn>1600-0641</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUtv1DAUhS0EokPhD7BAkdiwaML1MzaqkKop0EojdQNsLcd2ZhzlMdiTSP33eDSlgi5Y3YW_c-71OQi9xVBhwOJjV3U7v68IEKhAVUDxM7TCAqAEwfBztMqQLCWp5Rl6lVIHABQUe4nOKAUqGaUrxNd3P2-vS6w-Fdch2Wnx8f6icMFsxykdgk2FGV3h4rwtnF98P-0HPx5eoxet6ZN_8zDP0Y-vX76vb8rN3bfb9dWmtFyKQylANE3rKePONKpm0rrakpowDKo2oq05GJBOKEFbgiX2DXEcSyIls4IpQ8_R55Pvfm4G72xeHU2v9zEMJt7ryQT978sYdno7LbrmjNaizgYXJ4PdE9nN1UaHMfk4aGCYgKB8wRn_8LAvTr9mnw56yKH4vjejn-akCWNKcSU5zej7J2g3zXHMaWjCQSpMMTtS5ETZOKUUfft4BAZ9LFF3-liiPpaoQelcYha9-_vXj5I_rWXg8gT4nP0SfNTJBj9a70L09qDdFP7n_xvDM6qx</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Asselah, Tarik</creator><creator>Durantel, David</creator><creator>Pasmant, Eric</creator><creator>Lau, George</creator><creator>Schinazi, Raymond F.</creator><general>Elsevier B.V</general><general>Elsevier Science Ltd</general><general>Elsevier</general><general>European Association for the Study of the Liver. Published by Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1881-8762</orcidid></search><sort><creationdate>20210101</creationdate><title>COVID-19: Discovery, diagnostics and drug development</title><author>Asselah, Tarik ; Durantel, David ; Pasmant, Eric ; Lau, George ; Schinazi, Raymond F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c586t-606bbfe345dab9748cd7c27241097a6f750a08d6963f2181eb2d5182884c649a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antiviral agents</topic><topic>Antiviral Agents - pharmacology</topic><topic>Coronaviridae</topic><topic>Coronavirus</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - diagnosis</topic><topic>COVID-19 - physiopathology</topic><topic>COVID-19 Drug Treatment</topic><topic>Cytokine storm</topic><topic>Cytokines</topic><topic>Dexamethasone</topic><topic>Diabetes mellitus</topic><topic>Drug Development</topic><topic>Drug Discovery</topic><topic>Drug Repositioning</topic><topic>Drug repurposing</topic><topic>Genome, Viral</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immunity, Innate</topic><topic>Immunosuppressive agents</topic><topic>Intravenous administration</topic><topic>Life Sciences</topic><topic>Pandemics</topic><topic>Pathogenesis</topic><topic>Remdesivir</topic><topic>Respiratory distress syndrome</topic><topic>Respiratory Distress Syndrome - virology</topic><topic>Review</topic><topic>Risk Factors</topic><topic>RNA viruses</topic><topic>SARS-CoV-2</topic><topic>SARS-CoV-2 - drug effects</topic><topic>SARS-CoV-2 - genetics</topic><topic>Serological tests</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Asselah, Tarik</creatorcontrib><creatorcontrib>Durantel, David</creatorcontrib><creatorcontrib>Pasmant, Eric</creatorcontrib><creatorcontrib>Lau, George</creatorcontrib><creatorcontrib>Schinazi, Raymond F.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Asselah, Tarik</au><au>Durantel, David</au><au>Pasmant, Eric</au><au>Lau, George</au><au>Schinazi, Raymond F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COVID-19: Discovery, diagnostics and drug development</atitle><jtitle>Journal of hepatology</jtitle><addtitle>J Hepatol</addtitle><date>2021-01-01</date><risdate>2021</risdate><volume>74</volume><issue>1</issue><spage>168</spage><epage>184</epage><pages>168-184</pages><issn>0168-8278</issn><issn>1600-0641</issn><eissn>1600-0641</eissn><abstract>Coronavirus disease 2019 (COVID-19) started as an epidemic in Wuhan in 2019, and has since become a pandemic. Groups from China identified and sequenced the virus responsible for COVID-19, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and determined that it was a novel coronavirus sharing high sequence identity with bat- and pangolin-derived SARS-like coronaviruses, suggesting a zoonotic origin. SARS-CoV-2 is a member of the Coronaviridae family of enveloped, positive-sense, single-stranded RNA viruses that infect a broad range of vertebrates. The rapid release of the sequence of the virus has enabled the development of diagnostic tools. Additionally, serological tests can now identify individuals who have been infected. SARS-CoV-2 infection is associated with a fatality rate of around 1–3%, which is commonly linked to the development of acute respiratory distress syndrome (ARDS), likely resulting from uncontrolled immune activation, the so called “cytokine storm”. Risk factors for mortality include advanced age, obesity, diabetes, and hypertension. Drug repurposing has been used to rapidly identify potential treatments for COVID-19, which could move quickly to phase III. Better knowledge of the virus and its enzymes will aid the development of more potent and specific direct-acting antivirals. In the long term, a vaccine to prevent infection is crucial; however, even if successful, it might not be available before 2021-22. To date, except for intravenous remdesivir and dexamethasone, which have modest effects in moderate to severe COVID-19, no strong clinical evidence supports the efficacy of any other drugs against SARS-CoV-2. The aim of this review is to provide insights on the discovery of SARS-CoV-2, its virology, diagnostic tools, and the ongoing drug discovery effort.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>33038433</pmid><doi>10.1016/j.jhep.2020.09.031</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0002-1881-8762</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0168-8278
ispartof Journal of hepatology, 2021-01, Vol.74 (1), p.168-184
issn 0168-8278
1600-0641
1600-0641
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7543767
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Antiviral agents
Antiviral Agents - pharmacology
Coronaviridae
Coronavirus
Coronaviruses
COVID-19
COVID-19 - diagnosis
COVID-19 - physiopathology
COVID-19 Drug Treatment
Cytokine storm
Cytokines
Dexamethasone
Diabetes mellitus
Drug Development
Drug Discovery
Drug Repositioning
Drug repurposing
Genome, Viral
Humans
Immune response
Immunity, Innate
Immunosuppressive agents
Intravenous administration
Life Sciences
Pandemics
Pathogenesis
Remdesivir
Respiratory distress syndrome
Respiratory Distress Syndrome - virology
Review
Risk Factors
RNA viruses
SARS-CoV-2
SARS-CoV-2 - drug effects
SARS-CoV-2 - genetics
Serological tests
Severe acute respiratory syndrome coronavirus 2
Viruses
title COVID-19: Discovery, diagnostics and drug development
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T18%3A21%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COVID-19:%20Discovery,%20diagnostics%20and%20drug%20development&rft.jtitle=Journal%20of%20hepatology&rft.au=Asselah,%20Tarik&rft.date=2021-01-01&rft.volume=74&rft.issue=1&rft.spage=168&rft.epage=184&rft.pages=168-184&rft.issn=0168-8278&rft.eissn=1600-0641&rft_id=info:doi/10.1016/j.jhep.2020.09.031&rft_dat=%3Cproquest_pubme%3E2508913143%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2508913143&rft_id=info:pmid/33038433&rft_els_id=S0168827820336758&rfr_iscdi=true